Ischemic Brain Stroke and Mesenchymal Stem Cells: An Overview of Molecular Mechanisms and Therapeutic Potential

Table 2

Summary of clinical trial study using MSC-based therapy for ischemic stroke.

Sr#	ClinicalTrials.gov identifier	Study type	Type of cell	Type of stroke	Patients demography	Delivery route	Dose safety & efficacy	Study objectives
1	NCT01019733	Phase n/a interventional	Autologous hematopoietic (CD34+) cells	Hypoxic/ischemic brain injury	18 participants of 1 year to 8 years (child) of all sexes	Intrathecal administration	5 to 10 mL of stem cells will be infused intrathecally	An overall 4.7-month increase in developmental age according to the Battelle Developmental Inventory PM
2	NCT04590118	Phase randomized open-label	Allogeneic umbilical-cord mesenchymal stem cells	Ischemic stroke	18 years or older clinical diagnosis of ischemic stroke for more than 6month	Single intravenous infusion of it-hMSC for ischemic stroke patients	Single intravenous infusion of	The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of a single injection of it-hMSC in patients with ischemic stroke in a multicenter, blind, randomized, placebo-controlled trial
3	NCT03186456	Phase I/II interventional	Allogeneic umbilical-cord mesenchymal stem cells	Cerebral infarction	18 years or older, diagnosis of more than 6 months exhibiting functional deficit	Intravenous infusion	Single intravenous infusion of it-hMSC/kg	A phase I/IIa study to evaluate the safety, tolerability, and preliminary efficacy of a multicenter, blind, randomized, placebo-controlled single injection of it-hMSC in patients with ischemic stroke
4	NCT03176498	Phase I/phase I, nonrandomized	Allogeneic umbilical-cord mesenchymal stem cells	Cerebral infarction	20 years to 75 years, proved cerebral infarction by CT or MRI.	Intravenous infusion	The experimental group received allogeneic umbilical cord mesenchymal stem cell and aspirin enteric-coated tablets, 0.1 g/d by mouth	The effects of human umbilical cord mesenchymal stem cell therapy on neurological function for cerebral infarction patients in convalescent period
5	NCT04097652	Phase I randomized	Human umbilical cord-derived mesenchymal stem cells (UMC119-06)	Transient ischemic attack	9 patients with 20 years to 80 years onset of ischemic stroke within 48 to 168 hours before the start of treatment	Intravenous infusion.	Low does to a high dose of UMC119-06 with three months of time frame	The safety and tolerability after intravenous infusion of UMC119-06 in subjects with acute ischemic stroke
6	NCT04093336	Phase I/II nonrandomized	Human umbilical cord mesenchymal stem cells	Cerebral infarction/acute ischemic stroke	Patients aged 18~80 years with a clinical diagnosis of ischemic stroke for more than 6 months	Intravenous transplantation	Intravenous MSCs /kg as a single dose and standardized treatment of acute ischemic stroke	Effect of human umbilical cord mesenchymal stem cell (MSC) transplantation for prognosis of acute cerebral infarction patients
7	NCT01310114	Phase II randomized	Human placenta-derived cells (PDA001)	Acute ischemic stroke	Patients of all sexes with 18 years to 80 years of age	Intravenous infusion	cells in 240 mL per infusion	A phase 2A, prospective, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety of intravenous infusion of human placenta-derived cells (PDA001) for the treatment of adults following ischemic stroke
8	NCT01297413	Phase I/II, randomized open-label	Allogeneic adult mesenchymal bone-marrow stem cells	Ischemic stroke	18 years and older with clinical diagnosis of ischemic stroke for longer than 6 months	Intravenous infusion	Intravenous one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells	A phase I/II, multicenter, open-label study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of allogeneic mesenchymal bone marrow cells to subjects with ischemic stroke
9	NCT02580019	Phase II randomized	Human umbilical cord mesenchymal stem cells	Ischemic stroke	18 years to 70 years confirmed diagnosis of intracerebral ischemic stroke in three months by magnetic resonance imaging(MRI)	Intravenous infusion	A single dose of hUC-MSC will be treated to patients	Cell therapy by intravenous injection of umbilical cord derived mesenchymal stem cells after stroke